Suppr超能文献

心律失常性右室发育不良/心肌病中心律失常的消融:基于心内膜-心外膜标测和消融的无心律失常生存。

Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation.

机构信息

Texas Cardiac Arrhythmia Institute at St David's Medical Center, Austin, TX, USA.

出版信息

Circ Arrhythm Electrophysiol. 2011 Aug;4(4):478-85. doi: 10.1161/CIRCEP.111.963066. Epub 2011 Jun 10.

Abstract

BACKGROUND

In patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy, freedom from ventricular arrhythmias (VAs) after endocardial ablation is limited. We compared the long-term freedom from recurrent VAs by using endocardial-alone ablation versus endo-epicardial substrate-based ablation.

METHODS AND RESULTS

Forty-nine patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing ablation of ventricular tachycardia (VT) were divided into 2 groups: endocardial-alone ablation (group 1, n = 23) and endo-epicardial ablation (group 2, n = 26). All patients had an implantable cardioverter-defibrillator (ICD). Conventional and 3D mappings were used to determine the mechanism of induced VTs and to identify area of "scar" or "abnormal" myocardium. All critical sites responsible for VTs and points with "abnormal" potential were targeted for ablation from endocardium (group 1) or from both endocardium and epicardium (group 2). The procedural end point was noninducibility of sustained, monomorphic VT with isoproterenol. The presence of frequent premature ventricular contractions at the end of ablation was recorded. Patients were followed up by ECG, Holter, and ICD interrogation. After a follow-up of at least 3 years, freedom from VAs or ICD therapy was 52.2% (12/23) in group 1 and 84.6% (22/26) in group 2 (P = 0.029), with 21.7% (5/23) and 69.2% (18/26) patients off antiarrhythmic drugs (P < 0.001), respectively. Compared with patients with no premature ventricular contractions after ablation, patients with frequent premature ventricular contractions after ablation were more likely to have VA recurrence/ICD therapy [3/33 (9%) versus 12/16 (75%); log-rank P<0.001].

CONCLUSIONS

An endo-epicardial-based ablation strategy achieves higher long-term freedom from recurrent VAs off antiarrhythmic therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy when compared with endocardial-alone ablation. The presence of ≥ 10 premature ventricular contractions per minute after ablation is associated with more VA recurrence.

摘要

背景

在致心律失常性右室心肌病患者中,心内膜消融后免于室性心律失常(VA)的比例有限。我们比较了心内膜消融与心内膜-心外膜基质消融治疗复发性 VA 的长期效果。

方法和结果

49 例致心律失常性右室心肌病患者行 VT 消融术,分为两组:心内膜消融组(组 1,n=23)和心内膜-心外膜消融组(组 2,n=26)。所有患者均植入植入式心律转复除颤器(ICD)。采用常规和 3D 标测来确定诱发性 VT 的机制,并确定“瘢痕”或“异常”心肌的区域。所有负责 VT 的关键部位和具有“异常”电位的点均在心内膜(组 1)或心内膜和心外膜(组 2)进行消融。消融终点为异丙肾上腺素诱导的持续性单形性 VT 不再诱发。记录消融结束时频发室性期前收缩的情况。通过心电图、动态心电图和 ICD 随访来随访患者。至少随访 3 年后,组 1 的 VA 或 ICD 治疗无复发率为 52.2%(12/23),组 2 为 84.6%(22/26)(P=0.029),分别有 21.7%(5/23)和 69.2%(18/26)的患者停用抗心律失常药物(P<0.001)。与消融后无频发室性期前收缩的患者相比,消融后频发室性期前收缩的患者更有可能出现 VA 复发/ICD 治疗[3/33(9%)与 12/16(75%);log-rank P<0.001]。

结论

与单纯心内膜消融相比,心内膜-心外膜基质消融策略可使致心律失常性右室心肌病患者获得更高的长期免于抗心律失常药物治疗的复发性 VA 效果。消融后每分钟≥10 次频发室性期前收缩与 VA 复发相关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验